Skip to content

Will Inovio Pharmaceuticals (INO) be the COVID-19 winner?

What’s up with Inovio Pharmaceuticals?

Inovio Pharmaceuticals (INO) opened at $13.20, which means the stock is down 15.40% from yesterday’s closing price of 13.74. Today, the company has a high of $13.42 and a low of $11.60. The company has a market cap of $1.76 billion with a 52-week high of $19.36 and a 52-week low of $1.92.

Advertisements

What about the future for Inovio Pharmaceuticals

The high forecast for Inovio Pharmaceuticals is 19.00 while the low is 7.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. Inovio Pharmaceuticals has a weak forecast. A weak forecast is due to the company posting consistent losses in their earning reports. The future outlook does not seem too bright as this could potentially cause the company to file for bankruptcy.. Based on this information INO seems to be a risky buy.

About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. The firm’s drug candidates include SynCon immunotherapies which helps break the immune system’s tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Leave a Reply

%d bloggers like this: